AI/CT Combination for Assessing Pulmonary Embolism Severity Gets FDA Nod
Facilitating expedited assessment of pulmonary embolism severity, the emerging artificial intelligence (AI) tool Rapid RV/LV reportedly calculates the right ventricle/left ventricle (RV/LV) ratio within minutes of a computed tomography pulmonary angiogram (CTPA).
The Food and Drug Administration (FDA) has granted 510(k) clearance for RapidAI’s Rapid RV/LV, an artificial intelligence (AI)-powered modality that provides expedited calculation of the right ventricle/left ventricle (RV/LV) ratio, a key factor for determining pulmonary embolism (PE) severity.
Integrated with the company’s previously FDA-cleared Rapid PE platform, Rapid RV/LV identifies potential right heart strain with automated measurement of RV/LV ratios within minutes of analyzing a computed tomography pulmonary angiogram (CTPA), according to RapidAI.
Peter Monteleone, M.D., FACC, FSCAI, said Rapid RV/LV will be a significant advance in the evaluation of elevated risk for pulmonary embolism, a disease that is commonly underdiagnosed.
“The ability to access the RV/LV ratio along with CTPA images will allow clinicians to quicky identify patients who would benefit from further treatment, improving patient outcomes and saving lives,” emphasized Dr. Monteleone, an interventional cardiologist at Ascension Texas Cardiovascular in Austin, Tx., and assistant professor in the Department of Internal Medicine at Dell Medical School at the University of Texas at Austin. “This will have a profound impact on our PE program here at Ascension.”
(Editor’s note: For related content, see “Can Deep Learning Assessment of X-Rays Improve Triage of Patients with Acute Chest Pain?” and “Viz.ai Gets FDA Clearance for New RV/LV Ratio Algorithm.”)
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
